ACM
BMRN icon

Aster Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aster Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$514K Buy
8,988
+8,254
+1,125% +$452K 0.11% 258
2026
Q1 		$51.9K Sell
734
-2,647
-78% -$154K 0.02% 433
2025
Q4 		$201K Buy
+3,381
New +$184K 0.09% 223
2025
Q3 		– Sell
-2,071
Closed -$114K – 993
2025
Q2 		$114K Sell
2,071
-38,243
-95% -$2.25M 0.03% 492
2025
Q1 		$2.87M Buy
+40,314
New +$2.71M 0.53% 32

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Aster Capital Management's BMRN Position: Q2 2026 in Review

Aster Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 1,125% in Q2 2026, buying an estimated $452K and bringing the position to 8,988 shares worth $514K. The position accounts for 0.11% of the portfolio, ranked #258.

Aster Capital Management first reported a position in BMRN in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.87M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Aster Capital Management held 8,988 shares of BioMarin Pharmaceuticals worth $514K as of Q2 2026.
  • Aster Capital Management bought 8,254 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $452K.
  • BioMarin Pharmaceuticals made up 0.11% of Aster Capital Management's portfolio in Q2 2026, its #258 holding.
  • Aster Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Aster Capital Management's BioMarin Pharmaceuticals position peaked at $2.87M in Q1 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.